Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study.

Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, Jacobson SH, Locatelli F, Port FK, Robinson BM.

J Am Soc Nephrol. 2016 Jul;27(7):2205-15. doi: 10.1681/ASN.2015060673. Epub 2015 Nov 18.

2.

Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.

Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.

J Manag Care Pharm. 2008 Nov-Dec;14(9):858-69.

3.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
4.

Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.

Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, Zager P, Pisoni RL, Port FK, Robinson BM.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1814-21. doi: 10.2215/CJN.02600315. Epub 2015 Aug 18.

5.

Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK.

Am J Kidney Dis. 2004 Jul;44(1):94-111.

PMID:
15211443
6.

Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.

Wetmore JB, Peng Y, Monda KL, Kats AM, Kim DH, Bradbury BD, Collins AJ, Gilbertson DT.

Am J Nephrol. 2015;41(4-5):354-61. doi: 10.1159/000431335. Epub 2015 Jun 17.

PMID:
26107376
7.

Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).

Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM.

JAMA Intern Med. 2014 May;174(5):699-707.

8.

Renal anemia treatment with ESA in hemodialysis patients in relation to early versus late referral in everyday clinical practice in Central and Eastern European countries: baseline data.

Malyszko J, Drozdz M, Zolkiewicz A, Rutkowski B.

Kidney Blood Press Res. 2012;35(1):58-67. doi: 10.1159/000330496. Epub 2011 Aug 26.

9.

Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.

Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ.

J Am Soc Nephrol. 2016 Oct;27(10):3129-3138. Epub 2016 Feb 25.

10.
11.

Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.

Hasegawa T, Zhao J, Fuller DS, Bieber B, Zee J, Morgenstern H, Hanafusa N, Nangaku M.

Am J Nephrol. 2017;46(1):11-17. doi: 10.1159/000477217. Epub 2017 Jun 1.

12.

Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.

Luo J, Jensen DE, Maroni BJ, Brunelli SM.

Am J Kidney Dis. 2016 Nov;68(5):763-771. doi: 10.1053/j.ajkd.2016.05.031. Epub 2016 Aug 12.

13.

Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management?

Turenne MN, Cope EL, Porenta S, Mukhopadhyay P, Fuller DS, Pearson JM, Dahlerus C, Lantz B, Tentori F, Robinson BM.

J Am Soc Nephrol. 2015 Mar;26(3):754-64. doi: 10.1681/ASN.2013111232. Epub 2014 Oct 9.

14.

International trends in erythropoietin use and hemoglobin levels in hemodialysis patients.

McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D.

Kidney Int. 2010 Jul;78(2):215-23. doi: 10.1038/ki.2010.108. Epub 2010 Apr 28.

15.

Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study.

Monda KL, Joseph PN, Neumann PJ, Bradbury BD, Rubin RJ.

BMC Nephrol. 2015 May 1;16:67. doi: 10.1186/s12882-015-0059-8.

16.

Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.

Collins AJ, Monda KL, Molony JT, Li S, Gilbertson DT, Bradbury BD.

Am J Kidney Dis. 2014 Jun;63(6):997-1006. doi: 10.1053/j.ajkd.2013.10.052. Epub 2013 Dec 4.

PMID:
24315770
17.
18.

Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.

Stroupe KT, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Durazo-Arvizu R, Browning MM, Hynes DM.

Pharmacotherapy. 2012 Nov;32(11):988-97. doi: 10.1002/phar.1134. Epub 2012 Oct 26.

PMID:
23108695
20.

A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.

Brophy GM, Sheehan V, Shapiro MJ, Lottenberg L, Scarlata D, Audhya P; ASSESS Study Group and Amgen Inc.

Clin Ther. 2008 Dec;30(12):2324-34. doi: 10.1016/j.clinthera.2008.12.024.

PMID:
19167591

Supplemental Content

Support Center